Phase II, double blind, randomised, controlled study to evaluate immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals Hib-menAC vaccine (Ghana)

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2004
This article has no abstract
Epistemonikos ID: 7db5efd4d7634d4c0e1182484474f892a12a7ba6
First added on: Jan 17, 2025